Therapeutic potential of rWnt5A in curbing Leishmania donovani infection
Infection and Immunity · 2023
DOI: 10.1128/iai.00267-23 ↗Kurz gefasst
Fachartikel in der Zeitschrift Infection and Immunity, 2023. Verfasst von Shreyasi Maity und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cancer Biology & Inflammatory Disorder, CSIR-Indian Institute of Chemical Biology , Kolkata, West Bengal, India. Hauptthemen laut MEDLINE: Leishmania donovani, Leishmaniasis, Visceral. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Indian Council of Medical Research, CSIR | CSIR – Indian Institute of Chemical Biology, University Grants Commission.
Abstract (Originalsprache)
In view of the antagonism of Wnt5A signaling toward microbial pathogens, we were interested in evaluating the therapeutic potential of recombinant Wnt5A (rWnt5A) in curbing Leishmania donovani infection. Initially, using L. donovani -infected RAW 264.7 and peritoneal macrophages, we demonstrated that application of rWnt5A as opposed to the vehicle control to the infected cells significantly dampens L. donovani infection. Inhibition of infection was associated with increase in cell-associated reactive oxygen species (ROS), and blocked by the ROS production inhibitor diphenylene iodonium chloride (DPI). rWnt5A, but not the vehicle control (PBS: phosphate-buffered saline) administration to L. donovani -infected mice appreciably reduced the infection load, and inhibited disease progression as evident from the preservation of splenic white pulp architecture. rWnt5A administration, moreover, led to elevation of both cell-associated ROS and the activation of splenic T cells. Substantial increase in T cell-associated Interleukin-2 (IL-2) and Granzyme B (GRB) upon exposure of splenic lymphocytes harvested from rWnt5A-treated mice to L. donovani -infected RAW 264.7 macrophages in vitro validated the occurrence of L. donovani -responsive T cell activation in vivo . In summary, this study unveils the therapeutic potential of rWnt5A in curbing L. donovani infection and the progression of experimental visceral leishmaniasis possibly through increase in cellular ROS and T cell activation. Accordingly, it opens up a new avenue of investigation into the use of rWnt5A as a therapeutic agent for restraining the progression of drug-resistant L. donovani infection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cancer Biology & Inflammatory Disorder, CSIR-Indian Institute of Chemical Biology , Kolkata, West Bengal, India.
ORCID-Profile: Shreyasi Maity, Soham Sengupta
Förderung
- Indian Council of Medical Research
- CSIR | CSIR – Indian Institute of Chemical Biology
- University Grants Commission
- Council of Scientific and Industrial Research, India
Zitieren
APA
Maity, S., Sengupta, S., & Sen, M. (2023). Therapeutic potential of rWnt5A in curbing Leishmania donovani infection. Infection and Immunity. https://doi.org/10.1128/iai.00267-23
Vancouver
Maity S, Sengupta S, Sen M. Therapeutic potential of rWnt5A in curbing Leishmania donovani infection. Infection and Immunity. 2023. doi:10.1128/iai.00267-23
BibTeX
@article{Maity2023,
author = {Maity, Shreyasi and Sengupta, Soham and Sen, Malini},
title = {Therapeutic potential of rWnt5A in curbing Leishmania donovani infection},
journal = {Infection and Immunity},
year = {2023},
doi = {10.1128/iai.00267-23}
}
EUVIMED